Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $9.50

ProQR Therapeutics (NASDAQ:PRQR) has received a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $9.50.

A number of research firms recently issued reports on PRQR. Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Monday, March 10th. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 price objective for the company. HC Wainwright boosted their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, March 14th. Chardan Capital reiterated a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, March 14th. Finally, JMP Securities restated a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th.

Hedge Funds Weigh In On ProQR Therapeutics

A number of large investors have recently modified their holdings of PRQR. Jane Street Group LLC acquired a new stake in shares of ProQR Therapeutics in the fourth quarter valued at about $30,000. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $32,000. Alpine Global Management LLC bought a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $39,000. Two Sigma Securities LLC acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $40,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $54,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Price Performance

Shares of ProQR Therapeutics stock opened at $1.40 on Friday. ProQR Therapeutics has a 1 year low of $1.40 and a 1 year high of $4.62. The company has a market capitalization of $147.30 million, a P/E ratio of -4.38 and a beta of 0.24. The business has a 50-day moving average of $2.08 and a two-hundred day moving average of $2.59.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).